Endometrial Cancer
Conditions
Interventions
Observation group:None
Sponsors
Beijing Tsinghua Changgung Hospital
Eligibility
Sex/Gender
Female
Age
45 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Patients meeting the criteria for high-risk or increased-risk populations: According to the 2020 Recommendations for Endometrial Cancer Screening, patients are considered to be at high risk or increased risk if they have at least one of the following conditions: (1)Obesity, defined as body mass index (BMI) >=30 kg/m²; (2)Polycystic ovary syndrome (PCOS); (3)Use of estrogen without progestin opposition; (4)Late menopause (>55 years); (5)Nulliparity or primary infertility; (6)Long-term tamoxifen use, especially in patients older than 50 years or those who continue tamoxifen after menopause; (7)Age>= 45 years with diabetes mellitus; (8)Lynch syndrome; having a first-degree relative with Lynch syndrome without relevant genetic testing; or a personal or family history of colorectal cancer. 2.Underwent endometrial cytology examination, with retained cytology slides of qualified quality and complete staining; 3. Had a definite histopathological diagnosis that could serve as the gold standard for cytological interpretation; 4. The interval between endometrial cytology sampling and histological sampling was <=14 days, and no intervention that might affect the endometrial status was performed during this period.
Exclusion criteria
Exclusion criteria: 1. Unqualified cytology samples, including but not limited to the following conditions: (1)Slides lacking clear identification labels or being severely damaged and irreparable; (2)Severe cell overlap, glandular cells obscured by blood or inflammatory cells, poor fixation, or excessive drying of the specimen; (3)Contamination or other factors resulting in >=75% of glandular cells being uninterpretable; 2.An interval of more than 14 days between cytological and histopathological sampling, or the presence of factors during this period that might interfere with the endometrial status, such as intrauterine procedures, hormonal or endocrine therapy, radiotherapy, chemotherapy, or targeted therapy; 3. Incomplete clinical or ultrasound information; 4. Any other conditions deemed unsuitable for inclusion in this study by the investigators.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Area under the receiver operating characteristic curve (AUC) of the multimodal intelligent diagnostic model for endometrial cancer;Area under the receiver operating characteristic curve (AUC) of the cytology-based intelligent diagnostic model for endometrial cancer; | — |
Secondary
| Measure | Time frame |
|---|---|
| Sensitivity and specificity of the multimodal intelligent diagnostic model;Agreement between model-based interpretation and expert cytological interpretation; | — |
Countries
China
Contacts
Public ContactLei Zhang
Beijing Tsinghua Changgung Hospital
Outcome results
None listed